A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

Sponsor
AstraZeneca
Study ID
NCT06639087
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • AZD5462 — DRUG
    Participants will receive AZD5462 on top of dapagliflozin once daily.
  • Dapagliflozin — DRUG
    Participants will receive dapagliflozin once daily with AZD5462 or placebo.
  • Placebo — OTHER
    Participants will receive placebo on top of dapagliflozin once daily.

Study Details

A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment.

Key Dates

Start date
Sep 27, 2024
Status verified
Sep 2025
Primary completion
May 29, 2025
Completion
May 29, 2025

Study Design

Enrollment
8 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: AZD5462 + dapagliflozin
    Participants will receive AZD5462 on top of dapagliflozin once daily.
  • Placebo Comparator: Placebo + dapagliflozin
    Participants will receive placebo on top of dapagliflozin once daily.

Primary Outcome Measure

Change in sodium excretion [ Time Frame: From Baseline to Day 1 ]

Related Studies